• Users Online: 1102
  • Print this page
  • Email this page
Year : 2023  |  Volume : 9  |  Issue : 3  |  Page : 270-277

Efficacy and safety of huachansu capsules for the treatment of esophageal cancer: A systematic review and meta-analysis

1 Research Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation, Scool of Life Science and Biopharmaceutics, Shenyang PharmaceuticalUniversity, Shenyang, China
2 School of Biomedical Informatics, University of Texas Health Science Center, Houston, Texas, USA

Correspondence Address:
Dr. Jian Gong
Research Group of Jian Gong on Pharmacoepidemiology and Clinical Drug Evaluation, Shenyang Pharmaceutical University, Shenyang 110016
Login to access the Email id

Source of Support: None, Conflict of Interest: None

DOI: 10.4103/2311-8571.355009

Rights and Permissions

The objective of this study was to systematically evaluate the efficacy and safety of Huachansu capsules in the treatment of esophageal cancer. We searched all relevant Chinese and English documents in the Cochrane Library Clinical Controlled Trials, PubMed, EMBASE, CNKI, and VIP databases, from the time the databases were established to December 2020. The studies were selected according to the inclusion and exclusion criteria, and their quality was evaluated. We used RevMan 5.4 to conduct the meta-analysis of measurement indicators and intervention measures. Six randomized controlled trials comprising 526 patients with esophageal cancer were included in the study. Compared with radiotherapy and chemotherapy alone, oral Huachansu capsules combined with radiotherapy and chemotherapy improved the clinical efficacy (risk ratio [RR] = 1.35, 95% confidence interval [CI], 1.17–1.55, P < 0.0001), quality of life (weighted mean difference [MD] = 10.01, 95% CI [3.39–16.64], P = 0.003), and immune level (CD3+: MD = 4.99, 95% CI [3.70–6.29], P < 0.0001; CD4+: MD = 6.49, 95% CI [5.55–7.42], P < 0.0001; CD5+: MD = 0.20, 95% CI [0.11–0.28], P < 0.0001), and reduced toxic and side effects (reductions in white blood cell count: RR = 0.63, 95% CI [0.44–0.90], P = 0.01; Reductions in blood platelet: RR = 0.70, 95% CI [0.52–0.94], P = 0.02; Gastrointestinal reaction: RR = 0.73, 95% CI [0.59–0.89], P = 0.002). However, the number of included studies was small, and conclusions still need to be further verified using larger samples and high-quality randomized, double-blind controlled trials.

Print this article     Email this article
 Next article
 Previous article
 Table of Contents

 Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
 Citation Manager
 Access Statistics
 Reader Comments
 Email Alert *
 Add to My List *
 * Requires registration (Free)

 Article Access Statistics
    PDF Downloaded45    
    Comments [Add]    

Recommend this journal